/ Patients

About Access to Investigational Medicines

At Genentech, our focus is on enrolling patients in clinical trials to obtain the data required for review and approval by regulatory authorities, including the U.S. Food and Drug Administration (FDA).

Approval by regulatory authorities around the globe is the only way to make medicines broadly available to patients by prescription by a qualified healthcare provider. Therefore, our focus is in the best interest of the majority of patients with a serious or immediately life-threatening disease who require treatment.

We recognize that some patients with serious or immediately life-threatening diseases may not be eligible for any clinical trials and may not have other options. In rare circumstances, Genentech may provide patients with access to unapproved or investigational medicines outside the clinical trials process.

Types of Access

Patients may gain access to unapproved or investigational medicines through clinical trials, expanded access programs (EAPs), or compassionate use (CU) before they are approved by regulatory authorities.

  • Clinical Trials icon-down-arrow.png
  • Expanded Access Programs (EAPs) icon-down-arrow.png
  • Compassionate Use (CU)icon-down-arrow.png
  • How Patients Gain Access to Medicines Before They Are FDA-Approvedicon-down-arrow.png

Find Open Clinical Trials

Search clinicaltrials.gov to find out if a clinical trial exists for a specific medicine for a particular disease.